Actinic keratosis

7 trials 2 recruiting MedDRA PT
7 Registered trials
2 Recruiting
7 Unique sponsors
4 Unique IMPs
5 Commercial trials
Drug classes (ATC)
— ATC code not specified 3
D Dermatology (ATC D) 4
Mechanism of action (INN-stem analysis)
Unknown / small molecule 4 substances
Phase III: 2 Phase II: 2 Phase III/IV: 2 Phase I (Other): 1

Filter these 7 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 7 trials

Phase III

2 trials
  • Almirall S.A. Commercial
    TIRBANIBULIN
    2023-505487-11-00 5 countries 2023 n=269
    Ended
  • INFECTOPHARM Arzneimittel und Consilium GmbH Commercial
    POTASSIUM HYDROXIDE
    2024-514277-21-00 1 country 2025 n=630
    Recruiting

Phase II

2 trials
  • Laboratorios Normon S.A. Commercial
    IMIQUIMOD
    2024-515667-60-00 1 country 2020 n=68
    Ended
  • Vidac Pharma Ltd. Commercial
    TUVATEXIB
    2025-522482-30-00 1 country 2026 n=39
    Recruiting

Phase III/IV

2 trials
  • Centre Hospitalier Universitaire De Nantes Academic
    TIRBANIBULIN
    2023-509931-15-00 1 country n=59
    Pending
  • Clinica Universidad De Navarra Academic
    TIRBANIBULIN
    2023-508091-11-00 1 country 2024 n=40
    Ended

Phase I (Other)

1 trial
  • Ankh Life Sciences Limited Commercial
    IMP not specified
    2024-512893-86-00 1 country 2024 n=41
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Ankh Life Sciences Limited Commercial 1 Phase I (Other) 0
Laboratorios Normon S.A. Commercial 1 Phase II 0
Vidac Pharma Ltd. Commercial 1 Phase II 1
Almirall S.A. Commercial 1 Phase III 0
INFECTOPHARM Arzneimittel und Consilium GmbH Commercial 1 Phase III 1
Centre Hospitalier Universitaire De Nantes Academic 1 Phase III/IV 0
Clinica Universidad De Navarra Academic 1 Phase III/IV 0
New trials by year
2020
1
2023
1
2024
2
2025
1
2026
1
← All indication landscapes